Oncogenic SYK has been identified as an important driver of different hematologic malignancies, including B-cell lymphoma, chronic lymphocytic leukemia (CLL) and mantle cell lymphoma [15–17], and was identified as a target in AML with SYK inhibition exhibiting anti-leukemia activity in mouse models of AML [18]. Here, SYK is linked to leukemia.